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The objectives of the present study were to investigate the rate of S.aureus nasal carriage
and molecular characteristics in hospital and community settings in Bobo Dioulasso,
Burkina Faso. Nasal samples (n = 219) were collected from 116 healthy volunteers
and 103 hospitalized patients in July and August 2014. Samples were first screened
using CHROMagar Staph aureus chromogenic agar plates, and S. aureus strains were
identified by mass spectrometry. Antibiotic susceptibility was tested using the disk
diffusion method on Müller-Hinton agar. All S. aureus isolates were genotyped using DNA
microarray. Overall, the rate of S. aureus nasal carriage was 32.9% (72/219) with 29% in
healthy volunteers and 37% in hospital patients. Among the S. aureus isolates, only four
methicillin-resistant S. aureus (MRSA) strains were identified and all in hospital patients
(3.9%). The 72 S. aureus isolates from nasal samples belonged to 16 different clonal
complexes, particularly to CC 152-MSSA (22 clones) and CC1-MSSA (nine clones).
Two clones were significantly associated with community settings: CC1-MSSA and
CC45-MSSA. The MRSA strains belonged to the ST88-MRSA-IV or the CC8-MRSA-V
complex. A very high prevalence of toxinogenic strains 52.2% (36/69), containing
Panton-Valentine leucocidin- and EDIN-encoding genes, was identified among the
S. aureus isolates in community and hospital settings. This study provides the first
characterization of S. aureus clones and their genetic characteristics in Burkina Faso.
Altogether, it highlights the low prevalence of antimicrobial resistance, high diversity of
methicillin-sensitive S. aureus clones and high frequency of toxinogenic S. aureus strains.
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INTRODUCTION
Staphylococcus aureus is both a human commensal and a
frequent cause of clinically important infections in hospital and
community settings. It colonizes about one third of healthy
humans and is most often found in the nose (Kaspar et al.,
2016). As pathogenic agent, S. aureus causes a wide range of
infections (e.g., skin and soft tissue infections, sepsis, pneumonia,
osteomyelitis, endocarditis; Shittu et al., 2011). Epidemiological
studies of staphylococcal infections showed that nasal carriage is
a risk factor and usually the origin of the infection (Wertheim
et al., 2004). S. aureus treatment is complicated by the global
spread of methicillin-resistant S. aureus (MRSA) strains (Holden
et al., 2013).
Studies on the worldwide spread of S. aureus indicated that
clone predominance varies according to the continent: ST300 in
USA, ST59 in Asia, ST30/USA1100 in Southwest Pacific Oceania,
ST93 in Queensland and ST80 in European countries (Fluit
et al., 2015). In Africa, the limited epidemiological data suggest
that S. aureus clone distribution is particularly heterogeneous,
possibly due to the huge cultural and geographical diversity.
Similarly, toxinogenic strains are unequally distributed in the
different countries. For example, the prevalence of S. aureus
strains that produce Panton-Valentine Leukocidin (PVL) is of
0.3% in South Africa and of 100% in Tunisia (Schaumburg
et al., 2014; Abdulgader et al., 2015). Conversely, no data are
available on the distribution of S. aureus strains that produce
epidermal differentiation inhibitor (EDIN), one of the main
virulence factors involved in S. aureus diffusion. As several
pathogenic S. aureus clones, such as the European clone ST80-
MRSA-IV (Messad et al., 2013), express EDIN or EDIN-like
exotoxins, EDIN-positive strains could also be present in the
African continent, especially in Maghreb where the ST80 clone
is very common.
Few studies focused on S. aureus in hospital or community
settings in Burkina Faso, a low-income country of West Africa,
and nothing is known about clone circulation. The objectives
of the present study were to characterize the S. aureus isolates
in nasal specimens from hospitalized and healthy volunteers in
Bobo Dioulasso, Burkina Faso.
MATERIALS AND METHODS
Patients, Specimen Collection, and Ethical
Clearance
The study was approved by the local ethics committee
(Souro Sanou University Hospital board; authorization number:
MS/SG/CHUSS/DG/DL 2014-171, 2 July 2014). All participants
signed a written informed consent for participation in the study.
From 1st July to 31th August 2014, 116 randomly selected healthy
volunteers from the community and 103 patients hospitalized
(not for S. aureus infection) at the Souro Sanou University
Hospital (Bobo Dioulasso, Burkina Faso) for more than 48 h were
included prospectively and consecutively in the study. Souro
Sanou University Hospital is the major healthcare and referral
center for the southern and western regions of Burkina Faso.
During this period only one nasal swab sample by individuals
was collected excluding the possibility to study the dynamics of
SA nasal carriage over time (distinction between intermittent and
persistent carriers).
Nasal specimens from healthy volunteers and hospitalized
patients were collected using double-head flocked swabs
(Copan R©, Italy). The following epidemiological and clinical
data were recorded for all participants: age, gender, antibiotic
treatment during the past 3 months and hospital stays in the
previous year.
Microbiological Study of S. aureus
Nasal swab samples were plated on CHROMagar Staph aureus
chromogenic medium (BD Diagnostics, Sparks, Md.) and
examined after 24 and 48 h of incubation at 37◦C, following the
manufacturer’s recommendations. All mauve to orange/mauve
colonies were considered as positive for the presence of S.
aureus. The identification was confirmed by matrix-assisted
laser desorption ionization-time of flight (MALDI-TOF) mass
spectrometry (Bruker Daltonics, Germany). A multiplex real-
time PCR assay that targets bacterial nuc gene to distinguish
S. aureus from other Staphylococcus spp., and the mecA gene
for the detection of methicillin resistance was used. In all
confirmed S. aureus isolates, antibiotic susceptibilities were then
determined using the disk diffusion method on Müller–Hinton
agar with the following antibiotics: amoxicillin, amoxicillin-
clavulanic acid, oxacillin, gentamicin, tobramycin, tetracycline,
erythromycin, lincomycin, trimethoprim/sulfamethoxazole,
ofloxacin, fusidic acid, fosfomycin, and vancomycin. Results were
interpreted following the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) clinical breakpoints (Version
5.0; http://www.eucast.org/clinical_breakpoints/). Susceptibility
to methicillin was screened with the cefoxitin disk diffusion
method.
Oligonucleotide DNA Arrays and
Genotyping
Each S. aureus strain was analyzed at the INSERM laboratory in
Nîmes, France. The S. aureus genotyping kit (Alere Technologies
GmbH, Germany) was used according to previously detailed
protocols and procedures (Monecke et al., 2008). The DNA
microarray covers 332 different target sequences, including
species, capsule and agr group typing markers, resistance
genes (SCCmec, mecA, mecC) and genes encoding exotoxins or
Microbial Surface Components Recognizing Adhesive Matrix
Molecules (MSCRAMM). The affiliation of isolates to clonal
complexes (CCs) or sequence types (STs), defined based on
MLST and spa-typing (Monecke et al., 2008), was determined
by automated comparison of the hybridization profiles to a
collection of previously characterized reference strains (Monecke
et al., 2008, 2011).
Statistical Analysis
The nasal carriage rate and the frequency of MRSA strains were
analyzed relative to the demographic and clinical characteristics
of to the clonal complexes (CCs) and the expression of the
different virulence genes, using the Fisher’s exact test. Statistical
analyses were performed using the S-Plus 2000 software package
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(Insightful Corporation, Seattle, WA, USA) and results were
considered significant at p < 0.05.
RESULTS
Prevalence and Risk Factors of S. aureus
Nasal Carriage
During the study period, 219 subjects (116 healthy volunteers
and 103 hospitalized patients) were enrolled. The demographic
characteristics and possible risk factors for S. aureus colonization
in the two groups are shown in Table 1. Overall, the participants’
mean age was 24.1 years (±14.6) and 69.4% of them were males.
Among healthy volunteers, 13 (11%) had been hospitalized in
the previous year and 18 (16%) received antibiotics within the
3 months prior to inclusion in the study: fluoroquinolones (n =
9/18; 50%), ß-lactams (n= 7/18; 39%), or others (n= 2/18, 11%).
Among the hospitalized patients, 14 (14%) had been hospitalized
in the previous year. Significantly more patients than healthy
volunteers had received antibiotics within the last 3 months
(37 vs. 16%, p < 0.001). No significant difference could be
observed concerning the type of antibiotic treatment in the two
populations (Table 1).
S. aureuswas identified in the nasal samples of 32.9% (72/219)
participants (29.3% of healthy volunteers and 37% of hospitalized
patients; p = 0.23). Moreover, the rate of S. aureus carriage
varied in the different hospital services: 59% (16 of the 27
patients from this department) in the Surgery Department, 37%
(12/32) in the Pediatric, 32% (8/25) in the General Medicine, and
11% (2/19) in the Gynecology/Obstetric Department. Univariate
analysis did not identify any specific risk factor associated with
S. aureus nasal carriage in the whole population and the two
groups separately. Among the S. aureus isolates,MRSA frequency
was 0 (n = 0) in healthy volunteers and 3.9% (n = 4) in
hospitalized patients (p = 0.25), representing a total occurrence
of 1, 82%.
S. aureus Antimicrobial Susceptibility
Testing
Analysis of the in vitro activities of antimicrobial agents against
the 72 S. aureus isolates highlighted a low level of resistance
to all classical anti-staphylococcal treatments (Figure 1). All
isolates were susceptible to vancomycin, fosfomycin, and
fusidic acid. In strains isolated from hospitalized patients, the
trimethoprim/sulfamethoxazole association was always active;
in strains from healthy volunteers, oxacillin, ofloxacin, and
aminoglycosides (kanamycin, gentamicin, and tobramycin) were
always active. The highest resistance rates were observed
for amoxicillin (90%) followed by tetracycline (61%) and
erythromycin (54%), Single one MRSA isolate was resistant to
aminoglycosides and also to fluoroquinolones.
Distribution of S. aureus Clonal Complexes
Clonal complexes (CC) characterization in the 72 isolates allowed
comparing the S. aureus populations (diversity and origin) of
hospitalized patients and healthy volunteers and highlighted the
great diversity of S. aureus strains circulating in the studied
region (Table 2). ST 152-MSSA (n= 15) and CC1-MSSA (n= 8)
were the main clones isolated in hospitalized patients and healthy
volunteers, respectively. Overall, methicillin-susceptible S. aureus
(MSSA) strains belonged to many different CCs: ST 152 (n= 22),
CC5 (n = 14), CC1 (n = 9), ST 121 (n = 5), CC45 (n = 5), ST
707 (n = 2), ST 15 (n = 2), CC22 (n = 1), CC30 (n = 1), ST5
(n = 1), ST 30 (n = 1), CC9 (n = 1), ST 152 (n = 1). The Four
MRSA strains belonged either to the CC88-MRSA-IV or to the
CC8-MRSA-V lineage (no significant difference. Three isolates
were classified in unknown CCs.
Antibiotic Resistance and Virulence Gene
Profiles
The antibiotic resistance gene profiles obtained by DNA array
analysis were in full agreement with the data obtained by
TABLE 1 | Demographic characteristics, prevalence of Staphylococcus aureus nasal carriage and risk factors in the study population.
Characteristics Healthy volunteers Inpatients Total P
n = 116 n = 103 n = 219 H vs. I
Age (mean, SD), y 22.2 (11.7) 26.3 (17) 24.1 (14.6) NS
Hospitalization duration (mean, SD), day – 9.6 (4.2) – NA
HOSPITAL SERVICE
Pediatrics, n (%) – 32 (31.1) – NA
Surgery, n (%) – 27 (26.2) – NA
General Medicine, n (%) – 25 (24.3) – NA
Gynecology/obstetrics, n (%) – 19 (18.4) – NA
S. aureus carriers, n (%) 34 (29.3) 38 (36.9%) 72 (32.9) NS
MRSA carriers, n (%) 0 (0) 4 (3.9%) 4(1.82) NS
Previous hospitalization (in the last year), n (%) 13 (11.2) 14 (13.6) 27 (12.3) NS
Antibiotic treatment (in last 3 months), n (%) 18 (15.5) 38 (36.9) 56 (25.6) <0.001
ß-lactams, n (%) 7 (6) 16 (15.55) 23 (10.5) NS
Fluoroquinolones, n (%) 9 (7, 75) 13 (12.6) 22 (10) NS
Other antibiotics*, n (%) 2 (1.75) 9 (8.75) 11 (5) NS
*Tetracycline, doxycycline, co-trimoxazole (trimethoprim/sulfamethoxazole), erythromycin, chloramphenicol. NS, not significant; NA, not applicable.
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FIGURE 1 | Percentage of antimicrobial susceptibility for the Staphylococcus aureus strains isolated from healthy volunteers (n = 34) and hospitalized
patients (n = 38) (no significant differences between groups).
TABLE 2 | Clonal complex distribution of the Staphylococcus aureus
strains isolated from nasal samples of hospital patients and community
volunteers in Burkina Faso.
Hospital Community Total
n (%) n (%) n (%)
ST152-MSSA (PVL+) 15 (41.7) 7 (21.2) 22 (30.6)
CC5-MSSA 8 (22.1) 6 (18.2) 14 (19.4)
CC1-MSSA 1 (2.8) 8 (24.2) 9 (12.5)
ST121-MSSA (PVL+) 3 (8.2) 2 (6.1) 5 (6.9)
CC45-MSSA 0 (0) 5 (15.2) 5 (6.9)
CC88-MRSA 2 (5.6) 0 (0) 2 (2.8)
ST707-MSSA 2 (5.6) 0 (0) 2 (2.8)
CC8-MRSA 2 (5.6) 0 (0) 2 (2.8)
ST15-MSSA (PVL+) 0 (0) 2 (6.1) 2 (2.8)
CC22-MSSA 1 (2.8) 0 (0) 1 (1.4)
CC30-MSSA 1 (2.8) 0 (0) 1 (1.4)
ST5-MSSA (PVL+) 1 (2.8) 0 (0) 1 (1.4)
ST30-MSSA (PVL+) 0 (0) 1 (3.0) 1 (1.4)
CC9-MSSA 0 (0) 1 (3.0) 1 (1.4)
CC152-MSSA 0 (0) 1 (3.0) 1 (1.4)
None 2 (5.6) 1 (3.0) 3 (4.1)
TOTAL 38 (100) 34 (100) 72 (100)
conventional susceptibility testing. All MRSA isolates detected
with the cefoxitin disk diffusion test carried themecA gene within
the SCCmec mobile genetic element. MecC was not detected in
any of our samples. The most prevalent macrolide resistance
gene was ermC (25 isolates, 36.2%), whereas ermA was never
found. Only one aminoglycoside resistance gene (aacA-aphD)
was detected and only in one MRSA strain, confirming the still
high antimicrobial activity of this antibiotic family. The tetK
eﬄux gene (tetracycline resistance) was detected in 36 isolates
(52.2%). No van gene was detected in agreement with the in vitro
susceptibility data.
Some distinctive features regarding the virulence factor
profiles were observed. Between 14 and 42% of strains expressed
enterotoxin-coding genes [seg (n= 29, 42%), sek and seq (n= 12,
17.4% for each), and sea (n = 10, 14.5%)]. Conversely, genes
encoding haemolysins (hlg, hlgv, hlgA, hld), intracellular adhesion
proteins (icaA, icaC, icaD) or MSCRAMMs (ebpS, clfA, clfB,
fnbA, fnbB, and bbp) were detected in more than half and
often all strains. The agr1 allele was found in 42% of isolates
(n = 29). Toxinogenic genes were frequently present in our
strains. Although eta and etb (the genes encoding exfoliatin A
and B) were never detected, 44.9% (n = 31) and 29% (n = 20)
of isolates expressed the genes that encode PVL (lukS-PV/lukF-
PV) and toxic shock syndrome toxin 1 (TSST-1; tst), respectively.
Moreover, the prevalence of edin-positive isolates was 46.4%
(n = 32) and specifically, 14.5% (n = 10) of all isolates were
edinA-positive and 31.9% (n = 22) edin-B positive. The edin-B
and etD genes were always co-expressed.
Main Characteristics of the edin+ and
PVL+ S. aureus Isolates
The edin-B+ strains (n = 22) belonged to the ST152 clone (spa
type t355). In this clone, edin-B, etD, and lukF/lukS-PV genes
are associated. All 22 strains expressed the sarA regulon that
controls edin-B expression, and belonged to the agrI cluster.
No enterotoxin gene was detected. However, all edin-B+ strains
expressed one or more genes encoding haemolysins (hlgv, hlgA
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hla, and hlb), intracellular adhesion proteins (icaA, icaD), type 5
capsular polysaccharides (cap5), immune evasion proteins (sak,
scn), proteases (sspA, sspB), some MSCRAMMs (bbp, clfA, clfB,
cna, ebpS, fnbA, fnbB, sdrD), defensin (mprF), and hyaluronidases
(hysA1, hysA2).
The edin-A+ strains (n = 10) belonged to the clonal
complexes ST73 (CC5-MSSA, n = 8), ST5 (n = 1), and ST707
(n = 1). The ST5 strain co-expressed edin-A and lukF/lukS-PV.
All carried the sak, chp, scn hl, hlgA, hlgv, and hlA lukDE genes.
The strains belonging to the ST73 and ST5 clones expressedmany
virulence genes (e.g., the egc cluster, agrII, cap5, bbp, clfA, clfB,
ebpS, fib, fnbA, and fnbB). Finally, the ST707 strain harbored
distinctive virulence traits (sek, seq, agrIII, fnbB alone, sdrC and
sdrD).
Concerning the PVL+ strains (n = 31), they belonged to
the ST152 (n = 23), ST121 (n = 4), ST15 (n = 2), ST30
(n= 1), and ST5 (n = 1) clones. They all expressed agrI and
cap5, with the exception of the ST121 strains that carried agrIV
and cap8. Moreover, all PVL+ strains expressed genes encoding
haemolysins (hlgv, hlgA hla), immune evasion proteins (sak, scn)
and MSCRAMMs (bbp, clfA, clfB, ebpS, fnbA, fnbB).
DISCUSSION
This study provides the first characterization (clones and genetic
traits) of S. aureus samples isolated from nasal specimens in
Burkina Faso. Our findings highlight the low prevalence of
antimicrobial resistance, the high diversity of MSSA clones
and the high frequency of toxinogenic isolates among the
S. aureus strains that circulate in community and hospital
settings.
In Africa, S. aureus epidemiological data remain scarce.
The distribution of MRSA clones is relatively heterogeneous
on this continent with CC5 as the predominant clonal
complex in healthcare settings. The ≪Brazilian/Hungarian≫
clone (hospital-associated MRSA ST239/ST241-III) has been
identified in Maghreb, West Africa, and South African countries
(Schaumburg et al., 2014; Fluit et al., 2015). The European ST80-
IV clone is limited to Algeria, Egypt, and Tunisia (Schaumburg
et al., 2014; Fluit et al., 2015). The community clones ST8-
IV and ST88-IV have been reported both in hospital and
community settings inWest Africa. The ST88-MRSA-IV was also
found in our population associated with the ST8-MRSA-V clone
(Abdulgader et al., 2015). However, the percentage of MRSA
strains (2.3%) was very low in our panel, as previously reported
in Gabon (3%) (Kraef et al., 2015). On the other hand (and
this is the first major finding of this study), our data highlight
the high prevalence of strains harboring PVL-encoding genes
(45%). These genes encode a bi-component cytotoxin that binds
to the complement receptor C5a of neutrophils and that leads to
severe tissue necrosis due to its cytotoxic effect on granulocytes
(Dufour et al., 2002; Shallcross et al., 2013). Sub-Saharan Africa is
characterized by a high dissemination of PVL+ S. aureus strains
that mainly belong to three major clones: ST152, ST121, and
ST15 (Rasigade et al., 2010; Schaumburg et al., 2014). Our study
confirms this trend. The ST152 clone seems to be frequent and
widespread in West Africa (40–60% of all strains) both in the
community and in hospital settings (Ruimy et al., 2008; Shittu
et al., 2012; Kraef et al., 2015). This clone has also been detected
in Europe (Jappe et al., 2008; Perez-Roth et al., 2010; Krziwanek
et al., 2011), Turkey (Sudagidan and Aydin, 2010), and Haiti
(Rosenthal et al., 2014).
The high proportion of edin-positive MSSA (46%) strains in
our population is the second main finding of this study. Indeed,
such high prevalence has never been described before (14% in
a previous study) (Munro et al., 2011). Three edin alleles have
been characterized (Sugai et al., 1992; Yamaguchi et al., 2001,
2002). They all share similar biochemical activities toward Rho
proteins, but are characterized by different genetic backgrounds.
For instance, the edin-A gene is located on a plasmid, like edin-C,
and is closely associated with the gene encoding exfoliative toxin
B (Yamaguchi et al., 2001). EDIN proteins promote S. aureus
invasiveness, by favoring its translocation to the bloodstream
(Munro et al., 2010; Messad et al., 2013; Courjon et al., 2015).
In our population, edin-B was the most prevalent edin gene
associated with S. aureus nasal carriage. Many different S. aureus
clones harbor these genes, demonstrating the wide geographical
distribution of EDINs. In our population, edinB was more
frequently detected in isolates belonging to the ST152 clone,
like for the PVL+ strains. Therefore, our data indicate that
strains belonging to this clone can co-express edinB/etD/lukSF-
PV, which are the prevalent virulence markers detected in
infectious strains. More worrying, in Nigeria, the ST152 clone
has been associated with the SCCmec cassette (Shittu et al.,
2012). These findings suggest that these strains could pose serious
problems in the future, as potential reservoirs for resistance
and virulence factors, and they could lead to the emergence
and diffusion of PVL+ MRSA clones in Burkina Faso, with a
risk of severe infections, as recently discussed (Vignaroli et al.,
2016).
Nasal colonization often precedes clinical infection, frequently
caused by the same isolate (von Eiff et al., 2001). Therefore,
nasal carriage rates and the molecular characterization of the
colonizing isolates provide important insights into the risk of
S. aureus infection in Burkina Faso. The high proportion of
EDIN+ and PVL+ S. aureus observed in this study indicates that
conditions that increase the risk of inter-individual transmission
(e.g., skin-to-skin and skin-to-fomite contacts) could represent
important spreading routes in Burkina Faso. One the principal
limitation of this study was the absence of distinction between
intermittent and persistent carriers. It is now well-established
that this distinction is important as persistent carriers are at a
higher risk of developing active auto-infections than intermittent
and non-carriers (Wertheim et al., 2005; Muthukrishnan et al.,
2013). A larger sample of strains to study the dynamics of
SA nasal carriage over time in Burkina would provide a more
accurate measure of risk factors for infection according to patient
status (intermittent and persistent carriers).
Classically, mortality associated with severe S. aureus
infections is particularly high in emerging countries. Recent
studies have identified S. aureus as the main etiological agent
of many infections in Sub-Saharan Africa (Shittu et al., 2011).
Microbiologists and clinicians should be aware of the threat
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represented by the ST152 clone and implement the necessary
control measures to prevent its spread.
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